These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 14585917)
1. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Stephens J; Laskin B; Pashos C; Peña B; Wong J Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917 [TBL] [Abstract][Full Text] [Related]
2. [Cyclooxygenase-2 inhibitors in postoperative pain management]. Güneş Y; Işik G Agri; 2004 Jul; 16(3):7-16. PubMed ID: 15382000 [TBL] [Abstract][Full Text] [Related]
5. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791 [TBL] [Abstract][Full Text] [Related]
6. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors. Brooks PM; Day RO Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038 [TBL] [Abstract][Full Text] [Related]
8. COX-2-specific inhibition: implications for clinical practice. Pascucci RA J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177 [TBL] [Abstract][Full Text] [Related]
9. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Wynn RL Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547 [No Abstract] [Full Text] [Related]
10. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances]. Hinz B; Brune K Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892 [TBL] [Abstract][Full Text] [Related]
14. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Moride Y; Ducruet T; Rochon S; Lavoie F Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914 [TBL] [Abstract][Full Text] [Related]
15. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Harley C; Wagner S Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259 [TBL] [Abstract][Full Text] [Related]
16. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?]. Peretz A Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204 [TBL] [Abstract][Full Text] [Related]
17. Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Stephens JM; Pashos CL; Haider S; Wong JM Pharmacotherapy; 2004 Dec; 24(12):1714-31. PubMed ID: 15585440 [TBL] [Abstract][Full Text] [Related]
18. [Coxibs: cyclooxygenase-2 inhibitors]. Turnheim K Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832 [TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. Hochberg MC Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820 [TBL] [Abstract][Full Text] [Related]